Objective: One of the key events in post-angioplasty restenosis is the migration and proliferation of medial smooth muscle cells leading to neo-intima formation. This phase is mediated by several growth factors, mainly platelet-derived growth factor (PDGF), basic fibroblast growth factor (FGF2 / bFGF) and heparin-binding epidermal growth factor (HB-EGF). In this study, we have focused on the role of FGF2, which requires heparan sulfate proteoglycans (HSPG) as cofactors for binding and activation of its cell surface tyrosine kinase receptor. The aim of this study was to identify and explore the effect of novel FGF antagonists on vascular smooth muscle cell (VSMC) proliferation. Methods: We have recently identified a novel class of small, positively charged molecules sharing a porphyrin core as inhibitors of FGF2 and vascular endothelial growth factor (VEGF) activity. Here we investigated the inhibitory effect of these compounds on VSMC proliferation and their effect on heparin-induced FGF receptor activity. Results: We found that these molecules exert a marked inhibitory effect on FGF2-mediated smooth muscle cell (SMC) proliferation, manifested by reduced cell growth and DNA synthesis, which occurred in a dose-dependent manner with an IC of |1 mM of inhibitor. We demonstrate that the molecule, 5, 10, 15, 50 20-tetrakis (methyl-4-pyridyl)-21H, 23H-porphine tetra-p-tosylate salt (TMPP), inhibits binding of radiolabeled FGF2 to SMCs and to soluble FGF receptor 1 (FGFR1) in a manner that interferes with both ligand and receptor interactions with heparin, thereby blocking growth factor mediated SMC proliferation. Conclusion: We have identified an FGF antagonist, which may serve in clinical practice as a preventive measure of restenosis.
Introduction
The pathogenesis of restenosis consists of three cellular phases: (i) disruption of the endothelial layer, platelet Restenosis after successful percutaneous transluminal adhesion and aggregation, and the initiation of inflammacoronary angioplasty (PTCA) remains a major complicatory response; (ii) the granulation phase, involving smooth tion leading to recurrent acute coronary events and even muscle cell (SMC) migration and proliferation, and secredeath. Acute closure occurs in |4% of patients and may be tion of extra-cellular matrix; and (iii) the final remodeling partially resolved by using anti-thrombotic agents such as phase involving re-endothelization and matrix organization glycoprotein IIb / IIIa inhibitors [1] . The rate of restenosis [4] . Great experimental efforts have been focused on the is |30% after 6 months [2] and remains at least 20% crucial role of the granulation phase in the pathogenesis of following intra-coronary stent deployment [3] .
restenosis. This phase is mediated by several growth factors, mainly platelet derived growth factor (PDGF) [5] , heparin-binding epidermal growth factor (HB-EGF) [6] q This work was presented in part at the American Heart Association and basic fibroblast growth factor (FGF2) [7] .
71st Scientific Sessions.
Fibroblast growth factors constitute a family of poly- peptides involved in many vital processes including cell heparin matrix, FGF2 and an alkaline phosphatase tagged growth and differentiation, embryogenesis, angiogenesis FGFR (FRAP), was previously employed [17] . Briefly, the and wound healing [8] . Most types of cells found in the screen was conducted using 96-well plates to which restenotic area, e.g. endothelial cells, macrophages, SMCs heparin had been covalently attached. FGF2 was then and even T-cells, synthesize FGF2, which was shown to be bound to the plates through heparin-FGF2 interactions involved in the atherosclerotic process [9] . FGF2 is highly followed by the addition of FRAP and the compounds to mitogenic for vascular SMCs [10] .
be screened for their modulation of heparin-FGF, re-A common feature of FGF family members is their high ceptor-heparin and receptor-FGF interactions. The endaffinity towards heparin and heparan sulfate proteoglycans point of the assay measures the alkaline phosphatase (AP) (HSPGs). The interaction between FGF2 and HSPG encatalyzed formation of a chromogenic product [18] , which hances high affinity binding to the FGF cell surface, is proportional to the amount of FRAP present on the tyrosine kinase receptor (FGFR), and is essential for plates as a heparin-FGF-FRAP ternary complex. Thus, a mediating receptor phosphorylation and receptor-mediated lowered or elevated AP value, relative to a control, would signal transduction [11, 12] . Several models have been indicate modulation of binding at one or more of the three suggested for the mechanism by which heparin or heparan levels of interaction that describe the FGF-FGFR-heparin sulfates enhance FGF-FGFR interaction and activation.
ternary complex. This screen has identified several comRecent studies have demonstrated that the interaction of pounds for their capability to inhibit soluble FGF receptor FGF2 with heparin-derived oligosaccharides can lead to binding to immobilized ligand. One potent inhibitor was 5, both FGF2 [13] and FGFR [14] dimerization and that 10, 15, 20-tetrakis (methyl-4-pyridyl)-21H, 23H-porphine either cis- [15] or trans-oriented [16] dimers of FGF2 can tetra-p-tosylate salt (TMPP). be formed. These can subsequently lead to dimerization and activation of the tyrosine kinase receptor.
2.3. Cells In a search for compounds that can block these interactions, we have recently identified a novel group of small SMCs isolated from bovine aortic media were kindly molecules capable of blocking FGF-FGFR interaction and provided by Professor Israel Vlodavsky. Cells were cultumor progression [17] . We found that these molecules tured in DMEM supplemented with 10% bovine calf serum directly interfere with the interaction of both FGF2 and (BCS), at 378C in 10% CO humidified incubators. 
. Identification of FGF receptor binding antagonists
synthesis was assayed using a cell harvester to measure the radioactivity incorporated into trichloroacetic (TCA)-in-A high throughput screening system composed of a soluble material.
2.6. Radiolabeling of recombinant growth factors indicated. After 1.5 h, the beads were precipitated and washed three times with 1 ml of 20 mM HEPES, pH 7.5, Recombinant growth factor proteins were labeled with 150 mM NaCl, 1% Triton X-100 and 10% glycerol 125 Na-I (1 mCi), using the chloramine-T method [11] .
(HNTG). In parallel, soluble EGF receptor Fc-IgG fusion Briefly, iodinated FGF2 was separated from free iodine on protein [20] was bound directly to protein-A beads and a heparin-Sepharose column; the eluted factors were incubated with radiolabeled EGF (5 ng / ml), heparin and divided into aliquots and kept at 2208C until use.
TMPP. Growth factors were crossed-linked to their receptors by adding disuccinimidyl suberate (DSS) (15 mM) in PBS for 2.7. Iodination of TMPP derivative P10016 by the 30 min at room temperature. Growth factor-receptor Bolton-Hunter technique complexes were boiled for 5 min and separated under reducing conditions by 7% SDS-polyacrylamide gel elecThe compound 5-(2,3,4,5,6-pentafluorophenyl)-trophoresis (SDS-PAGE). The gel was dried and exposed 10,15,20-tris(N-methyl-4-pyridylium) porphyrin triiodide to Kodak X-Omat AR film. was synthesized as previously described [17] . BoltonHunter reagent (5 mg) was dissolved in 1 ml of DMSO, and iodinated by the chloramine-T method according to the 2.10. Competitive inhibition of FGF2 binding to heparin manufacturer's recommendations. Coupling of the iodiby TMPP nated Bolton-Hunter reagent to P10016 was performed by 125 adding 21.4 mg of P10016 dissolved in 1.5 ml methanol to For competition assays, 50 ng of I-FGF2 was added 4.75 mg of the labeled Bolton-Hunter reagent dissolved in to a heparin coated 96-well plate (Carmida, Sweden) with 1.5 ml of methanol. After 1 h of stirring, ether was added increasing doses of TMPP. After a 2-h incubation the wells until the product formed a precipitate. The solvent was were washed twice with cold PBS (pH 7.5) containing 1.6 subsequently removed and the product was dried under a M NaCl and 25 mM HEPES in order to remove low stream of nitrogen. affinity bound FGF. High affinity binding of FGF2 to heparin was determined by extracting the FGF with cold PBS (pH 4) containing 1.6 M NaCl and 25 mM HEPES.
Binding of radiolabeled FGF2 to cell surface
The extracts were counted in a g counter. bound to protein-A beads, I-FGF2 (5 ng / ml), I-FGF9 90 min at room temperature, washed three times with 0.5 (5 mg / ml) and 50 mg / ml heparin. TMPP was added when ml NaCl 0.5 M, and counted by a g counter. 
Results
labeled FGF2 binding occurred in the presence of TMPP at a concentration as low as 1 mg / ml (Fig. 1) vitro and tumor progression in vivo [17] . In order to chemical cross-linking of I-FGF2 to soluble FGFR1 was evaluate the capacity of TMPP to inhibit FGF2-receptor carried out in the absence or presence of TMPP. As shown binding on SMC, we measured binding of radiolabeled in Fig. 2 , there is complete inhibition of the formation of a FGF2 to SMCs, which are known to express FGF retypical FGF2-receptor complex at TMPP concentrations ceptors. A significant dose-dependent inhibition of radioas low as 5 mg / ml, in agreement with the direct binding agarose-protein-A beads (EGFR-Fc). The radiolabeled ligands: I-FGF2, I-FGF9 or I-EGF, respectively, were added to the binding reaction in the presence of heparin, with and without TMPP 5 mg / ml. After 90 min, disuccinylimidyl suberate (0.15 mM in PBS) was added. The protein complexes were separated by electrophoresis on a 7.5% SDS-polyacrylamide gel and analyzed on X-ray film.
data (Fig. 1) . In order to determine the specificity of this with the FGFR protein, we radiolabeled its close analogue 125 effect, we tested the capacity of TMPP to inhibit the P10016 [17] with I using the Bolton-Hunter technique. ( Fig. 5, panel B Since SMCs are the key players in the development of a cyanogen bromide activated Sepharose beads. The beads neo-intima after successful PTCA, and FGF2 is known to were then incubated with radiolabeled FGF2. Regardless be a potent mitogen for SMCs, we investigated the of extensive washing, FGF2 remained specifically bound influence of TMPP on FGF2-mediated vascular SMC to TMPP (Fig. 3) . In contrast, incubation with EGF growth by directly measuring proliferation and also by a showed no binding affinity to TMPP. thymidine incorporation assay. Fig. 6 , panel A demonstrates a marked dose-dependent inhibitory effect on SMC 3.4. TMPP competitively inhibits FGF2 binding to growth over a period of time. At a dose of 2 mg / ml, TMPP immobilized heparin exerts more than 50% inhibition on cell growth. TMPP also significantly inhibits DNA synthesis in SMCs in a In order to investigate the role of heparin in TMPPdose-dependent manner (Fig. 6, panel B) , with a similar 125 mediated FGF inhibition, I-FGF2 was bound to heparin response (Fig. 1) . covalently immobilized to a 96-well plate. As can be seen in Fig. 4 , the addition of increasing doses of TMPP results in competitive inhibition of FGF2-heparin interactions. development of arterial thickening produced in response to actions of FGF2 with its receptor. These compounds exert balloon injury. These models have utilized non-specific, high anti-mitogenic properties towards vascular SMCs as small molecular weight tyrosine kinase inhibitors [21] ,
shown by a reduction in FGF2 induced proliferation and antisense oligodeoxynucleotides to several cell cycle regthymidine incorporation. ulatory proto-oncogenes [22] , targeted gene delivery [23] All FGF members including FGF2 [11] [31] . It analogue [29] .
has been proposed that the minimum active structural unit Porphyrins have been of interest to chemists and mediof an FGF2-heparin complex is a properly cis-oriented cal scientists for over a century. It has been known for dimer bound to a sulfated decasaccharide [15] . Furthermany years that porphyrins interact with neoplastic tissues more, heparin was also found to directly interact with the [37] and the fact that porphyrins demonstrate high affinity extra-cellular domain of FGFR and this interaction is to tumorigenic cells in vitro and solid tumors in vivo, is essential for receptor activation [32, 33] . Recently, the well established [38, 39] . Moreover, porphyrin derivatives three-dimensional structures of FGFR and of FGF in have been used for the treatment of malignant tumors in complex with its receptor and heparin has been described combination with electromagnetic radiation or radioactive [14, 34, 36] . An attractive way to inhibit FGF2-receptor emissions. Since they strongly absorb light, many porbinding and activation would therefore be to interfere with phyrins are still being used as photosensitizers in photothe essential interaction of heparin with both the ligand and dynamic therapy (PDT) [39] .
the receptor. Here we demonstrate that TMPP, a positively charged
It is not at all clear how a small, moderately charged porphyrin analog, significantly inhibits FGF2 induced molecule such as TMPP inhibits heparin binding of both SMC proliferation by specifically interfering with the FGF2 and FGF9, but not that of FGF to their correessential interaction of both FGF2 and its receptor with sponding high affinity receptors. One possible explanation heparan sulfates. Interaction of the non heparin-binding is that this compound may structurally mimic a heparinepidermal growth factor with its receptor is, however, not binding motif shared by both FGF and FGFR. This is not inhibited by TMPP. TMPP seems to directly bind with obvious, as TMPP by itself does not seem to bind heparin significant affinity to both FGF2 and FGFR1 and this with high affinity. However, we and others have shown by binding could be competitively inhibited by heparin, experiments of site directed substitution of residues insuggesting that TMPP may block heparin-dependent intervolved in heparin binding in FGF2, that heparin binding of both FGF [35] and FGFR [32, 33] is highly sensitive to the process. There is data to suggest that several of these restricted changes within their putative heparin-binding strategies converge on a limited number of final common domains. A small, positively charged molecule such as pathways responsible for the restenotic phenotype. Lindner TMPP may competitively inhibit one such interaction, and Reidy [30] showed that systemic injection of a which may be sufficient to cause a deleterious effect on the neutralizing antibody against FGF2 prior to balloon catheformation of functional ligand-receptor complexes.
terization significantly decreased the induced SMC prolif-A critical question still remains as to why an inhibitor of eration by |80%. This study and several others support the only one of several pathways participating in the process concept that FGF2 signaling is one of these main pathof intimal hyperplasia results in significant attenuation of ways. It is therefore possible that the identified compound, 
